Ozmosi | EBP-05 Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

EBP-05

Alternative Names: EBP-05, EBP 05, EBP05
Clinical Status: Active
Latest Update: 2025-04-09
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Unknown

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Entera Bio
Company Location: JERUSALEM L3 9112002
Company CEO: Miranda J. Toledano
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for EBP-05

Countries in Clinic: Israel

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Hypoparathyroidism|Osteoporosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated
ENT-11-2023

P2

Active, not recruiting

Hypoparathyroidism|Osteoporosis

2026-05-01

50%

2025-04-10

Primary Completion Date|Primary Endpoints

Recent News Events

Date

Type

Title

11/29/2023

News Article

 Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

08/16/2023

News Article

 Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

02/15/2023

News Article

 Entera Bio Announces FDA's Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

10/06/2022

News Article

 Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions